Evidence map›Paper›PMID 35128658›Full record

ArticleTransfusion2022

Antibody profiles in COVID-19 convalescent plasma prepared with amotosalen/UVA pathogen reduction treatment.

Anil Bagri, Rafael R de Assis, Cheng-Ting Tsai, Graham Simmons, Zhen W Mei, Melissa Von Goetz, Michelle Gatmaitan, Mars Stone, Clara Di Germanio, Rachel Martinelli and 10 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Transfusion, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Trial
  2. Article
  3. Spectroscopic view on the interaction between the psoralen derivative amotosalen and DNA.Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology · 2024
    Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors at 5 institutions in 1 country.

Anil BagriTransfusion Medicine Research, Cerus Corporation, Concord, California, USA.ORCID 0000-0001-9679-1211
Rafael R de AssisDepartment of Physiology and Biophysics, School of Medicine, University of California Irvine, Irvine, California, USA.
Cheng-Ting TsaiEnable Biosciences Inc, South San Francisco, California, USA.
Graham SimmonsScientific Research Programs, Vitalant Research Institute, San Francisco, California, USA.
Zhen W MeiWing-Kwai and Alice Lee-Tsing Chung Transfusion Service, Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at University of California, Los Angeles, California, USA.ORCID 0000-0002-3810-2673
Melissa Von GoetzTransfusion Medicine Research, Cerus Corporation, Concord, California, USA.
Michelle GatmaitanTransfusion Medicine Research, Cerus Corporation, Concord, California, USA.
Mars StoneScientific Research Programs, Vitalant Research Institute, San Francisco, California, USA.
Clara Di GermanioScientific Research Programs, Vitalant Research Institute, San Francisco, California, USA.ORCID 0000-0002-6047-211X
Rachel MartinelliScientific Research Programs, Vitalant Research Institute, San Francisco, California, USA.
Orsolya DarstScientific Research Programs, Vitalant Research Institute, San Francisco, California, USA.ORCID 0000-0003-3682-4338
Jowin RioverosWing-Kwai and Alice Lee-Tsing Chung Transfusion Service, Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at University of California, Los Angeles, California, USA.
Peter V RobinsonEnable Biosciences Inc, South San Francisco, California, USA.
Dawn WardWing-Kwai and Alice Lee-Tsing Chung Transfusion Service, Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at University of California, Los Angeles, California, USA.ORCID 0000-0003-1672-740X
Alyssa ZimanWing-Kwai and Alice Lee-Tsing Chung Transfusion Service, Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at University of California, Los Angeles, California, USA.ORCID 0000-0002-1814-9319
David SeftelEnable Biosciences Inc, South San Francisco, California, USA.
Saahir KhanDivision of Infectious Diseases, Department of Medicine, University of California Irvine Health, Orange, California, USA.
Michael P BuschScientific Research Programs, Vitalant Research Institute, San Francisco, California, USA.
Philip L FelgnerDepartment of Physiology and Biophysics, School of Medicine, University of California Irvine, Irvine, California, USA.
Laurence M CorashTransfusion Medicine Research, Cerus Corporation, Concord, California, USA.ORCID 0000-0002-8615-9869
Pacific Research Institute · USCerus (United States) · USUniversity of California, Los Angeles · USEnable Biosciences (United States) · USUniversity of California, Irvine · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCOVID-19 convalescent plasma (CCP), from donors recovered from severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection, is one of the limited therapeutic options currently available for the treatment of critically ill patients with COVID-19. There is growing evidence that CCP may reduce viral loads and disease severity; and reduce mortality. However, concerns about the risk of transfusion-transmitted infections (TTI) and other complications associated with transfusion of plasma, remain. Amotosalen/UVA pathogen reduction treatment (A/UVA-PRT) of plasma offers a mitigation of TTI risk, and when combined with pooling has the potential to increase the diversity of the polyclonal SARS-CoV-2 neutralizing antibodies. STUDY DESIGN AND

methodsThis study assessed the impact of A/UVA-PRT on SARS-CoV-2 antibodies in 42 CCP using multiple complimentary assays including antigen binding, neutralizing, and epitope microarrays. Other mediators of CCP efficacy were also assessed.

resultsA/UVA-PRT did not negatively impact antibodies to SARS-CoV-2 and other viral epitopes, had no impact on neutralizing activity or other potential mediators of CCP efficacy. Finally, immune cross-reactivity with other coronavirus antigens was observed raising the potential for neutralizing activity against other emergent coronaviruses.

conclusionThe findings of this study support the selection of effective CCP combined with the use of A/UVA-PRT in the production of CCP for patients with COVID-19.

Indexed as

COVID-19Antibodies, NeutralizingAntibodies, ViralCOVID-19 SerotherapyFurocoumarinsHumansImmunization, PassiveSARS-CoV-2amotosalenAntibodies, NeutralizingAntibodies, ViralFurocoumarinsFFP transfusionplasma derivativestransfusion-transmitted disease-other

Identifiers

PMID35128658
PMCPMC9115453
OpenAlexW4210392642

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.